TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions

Giandomenico Roviello, Alberto D'Angelo, Marianna Sciortino, Enrico Mini, Stefania Nobili, Francesco De Logu, Daniela Massi

Research output: Contribution to journalReview article

Abstract

Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.

Original languageEnglish
Article number103011
JournalCritical Reviews in Oncology/Hematology
Volume152
Early online date31 May 2020
DOIs
Publication statusPublished - 31 Aug 2020

Cite this